IN191492B - - Google Patents

Info

Publication number
IN191492B
IN191492B IN776DE1999A IN191492B IN 191492 B IN191492 B IN 191492B IN 776DE1999 A IN776DE1999 A IN 776DE1999A IN 191492 B IN191492 B IN 191492B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Naresh Kumar
Chandrahas Khanduri
Mukesh Sharama
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN776DE1999 priority Critical patent/IN191492B/en
Priority to AU46040/00A priority patent/AU4604000A/en
Priority to EP00927651A priority patent/EP1185266A4/fr
Priority to PCT/IB2000/000708 priority patent/WO2000071124A1/fr
Publication of IN191492B publication Critical patent/IN191492B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN776DE1999 1999-05-25 1999-05-25 IN191492B (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IN776DE1999 IN191492B (fr) 1999-05-25 1999-05-25
AU46040/00A AU4604000A (en) 1999-05-25 2000-05-25 Amorphous form of fexofenadine hydrochloride
EP00927651A EP1185266A4 (fr) 1999-05-25 2000-05-25 Forme amorphe de chlorydrate de fexofenadine
PCT/IB2000/000708 WO2000071124A1 (fr) 1999-05-25 2000-05-25 Forme amorphe de chlorydrate de fexofenadine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN776DE1999 IN191492B (fr) 1999-05-25 1999-05-25

Publications (1)

Publication Number Publication Date
IN191492B true IN191492B (fr) 2003-12-06

Family

ID=11091185

Family Applications (1)

Application Number Title Priority Date Filing Date
IN776DE1999 IN191492B (fr) 1999-05-25 1999-05-25

Country Status (4)

Country Link
EP (1) EP1185266A4 (fr)
AU (1) AU4604000A (fr)
IN (1) IN191492B (fr)
WO (1) WO2000071124A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
HUP0400299A2 (en) * 2001-04-09 2007-08-28 Teva Pharma Polymorphs of fexofenadine hydrochloride
EE200400010A (et) * 2001-06-18 2004-02-16 Dr. Reddy's Laboratories Ltd. 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid
JP2005532356A (ja) 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
CA2560984A1 (fr) 2004-06-01 2005-12-15 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedure de preparation d'un medicament de forme amorphe
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
WO2011158262A1 (fr) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Forme polymorphe du chlorhydrate de fexofénadine, intermédiaires et procédé de préparation
KR101014010B1 (ko) * 2010-12-30 2011-02-14 주식회사 한국에너지관리 기체방울 수중 분산장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
CA1339136C (fr) * 1987-07-01 1997-07-29 Sailesh Amilal Varia Forme amorphe de l'aztreonam
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
DK0766668T3 (da) * 1994-05-18 2002-10-28 Aventis Pharma Inc Fremgangsmåde til fremstilling af vandfrie og hydratformer af som antihistaminer anvendelige piperidinderivater, polymorfer og pseudo-morfer deraf
CA2206592A1 (fr) * 1996-05-30 1997-11-30 Shu-Zhong Wang Methode de preparation de chlorhydrate de paroxetine amorphe
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives

Also Published As

Publication number Publication date
WO2000071124A1 (fr) 2000-11-30
AU4604000A (en) 2000-12-12
EP1185266A4 (fr) 2002-07-17
EP1185266A1 (fr) 2002-03-13

Similar Documents

Publication Publication Date Title
BE2015C057I2 (fr)
BE2016C007I2 (fr)
BE2015C018I2 (fr)
BE2014C017I2 (fr)
BE2013C051I2 (fr)
BE2013C020I2 (fr)
BE2013C015I2 (fr)
BE2013C001I2 (fr)
BE2012C036I2 (fr)
BE2011C004I2 (fr)
BE2010C011I2 (fr)
JP2002519753A5 (fr)
BRPI0017527B8 (fr)
JP2002528194A5 (fr)
BE2008C047I2 (fr)
BRPI0001672A2 (fr)
BRPI0001542A2 (fr)
JP2002517320A5 (fr)
JP2002517329A5 (fr)
BRPI0012675B8 (fr)
IN191492B (fr)
BRPI0017522A2 (fr)
ECSDI990530S (fr)
IN185227B (fr)
ECSDI990531S (fr)